# PROMETEO (NCT03802604)

> Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

No report yet. It can be ordered.

- Drugs tested: talimogene laherparepvec plus atezolizumab
- Indication: residual HER2-negative breast cancer after neoadjuvant chemotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03802604
- Phase: EARLY_PHASE1
- Status: COMPLETED
- Sponsor: SOLTI Breast Cancer Research Group
- Conditions: Breast Cancer
- Interventions: Talimogene laherparepvec; Atezolizumab
- Enrollment: 28
- Primary outcome: Rate of residual cancer burden class 0 and 1 (RCB0/1)

## Indexed commentary on PROMETEO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=prometeo-nct03802604

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03802604", "email": "<work email>"}; the inbox owner confirms by the emailed link.